Programme

Please note, this is an outline programme and is subject to minor changes. 

We acknowledge that this event has received sponsorship funding from pharmaceutical companies . The funding has been used to support the logistical aspects of the event, and the sponsoring companies have had no influence over the content, agenda, or selection of speakers for the main programme . All content is developed independently by the Scientific Committee to ensure that it meets the highest standards of scientific accuracy and objectivity . The sponsored symposia programme includes presentations that have been sponsored by industry and may involve discussion around the products of the sponsoring companies

Day 1 – Thursday 5 September 2024

10.00 — 12.30

Teaching Course 1

Basic Science: From Cells to Circuits: State-of-the-art tools for translational headache research

Parallel Room

10.00-10.05 Welcome & Introduction: Dr Philip R Holland & Dr Eloisa Rubio Beltran.
10.05-10.30 Cellular approaches to study headache in the lab Prof. Arn Van Den Maagdenberg (Leiden University, Netherlands)
10.30-10.50 Session focussed on opto/chemogenetics and the role of the brainstem LC. Prof. Tony Pickering (University of Bristol, UK)
10.55-11.20 Imaging methods to study brain function in preclinical models of migraine. Dr Philip R Holland (King’s College London)
11.20–11.30 Open source tools for migraine research. Dr Hui Zhou Chen (King’s College London, UK)
11.30-11.40 The potential of differentiated induced pluripotent stem cells to study neurological disease: where biology meets technology. Dr Jean-Phillipe Frimat (Leiden College, Netherlands)
11.40-11.50 Chemogenetic modulation of thalamic inhibition. Dr Eloisa Rubio Beltran (King’s College London, UK)
11.50–12.30 Interactive discussion and wrap up.
10.00 — 12.30

Teaching Course 2

Children and Adolescents

Chairs:  Amy Gelfand (UC San Francisco, USA) & Prab Prabhakar (Great Ormond Street Hospital & UCL, UK)

Parallel Room

Premonitory phase in children and adolescents

Nazia Karsan

King’s College London, UK

Biospychosocial approach to migraine management in children and young people

Massimiliano Valeriani

Ospedale Pediatrico Bambino Gesù, Italy

 

10.00 — 12.30

Teaching Course 3

Empowering Nurses / Allied Health Professionals

Chair: Fiona Greenwood (King’s College Hospital NHS Trust, UK)

Parallel Room

10:00-10:10 Introduction

Fiona Greenwood

King’s College London

10:10-10:40 Transition Clinic- From an Adult and Paediatric Perspective.
10:10- 10:25 Paediatric Perspective

Jo Mortimer and Kate Crumpler

GOSH, London.

10:25- 10:40 Adult Perspective Helen Delrosario Hull University Teaching Hospital.
10:40-11:00 Building a Novel Clinic: New Treatments and Access for Patients.

Claire Winstanley

University Hospitals of North Midlands.

11:20- 11:40 Leading a Team as an Allied Health Professional.

Anne-Marie Logan

St George’s Hospital, London

11:40- 12:00 Predictors to responding to Treatment/ How do we ensure that we provide patient centred care now that there are more options available?

Bethany Hill

St Thomas’s Hospital, London

12:00- 12:15

Panel Discussion (with all Speakers):

Question: The importance of allied health professional led clinics and the challenges that are/may be faced.

12.30 — 14.30

Registration & Networking Lunch

Richmond Suite/Parallel Room

14.00 — 17.30

Teaching Course 4

Getting to Grips with Migraine in Primary Care

Chair: Kay Kennis (Bradford GP Neurology Service, UK)

Parallel Room

This is a focused educational event delivered by experienced general practitioners with a special interest in headache, all of whom run headache clinics. It will give you more confidence to mange headache and, in particular, migraine.
A headache overview. What types of headaches do GPs see?
Children with headache

Katy Munro

National Migraine Centre, UK

Migraine and women’s health

Rebecca Walker

The Exeter Headache Clinic, UK

New migraine treatments

David Watson

Hamilton Medical Group, UK

Surviving the ten-minute headache consultation

David Kernick

The Exeter Headache Clinic, UK

15.30 — 15.45

Opening Session

Chair: Peter Goadsby
King’s College London

Kensington Suite

15.45 — 16.15

Plenary 1

MacDonald Critchley Lecture

Plenary 1

Introduction

MacDonald Critchley Lecture

Mark Weatherall

Imperial College, London

Antoinette Maassen van den Brink

Erasmus MC, Netherlands

Kensington Suite

Kensington Suite

16.30 — 17.30

Industry Symposia

Challenge Me! A half decade of monoclonal antibodies for migraine prevention: What we’ve
learnt and what’s next.

Teva Pharmaceuticals Europe B.V.

Kensington Suite

17.30 — 19.30

Welcome Reception

Richmond Suite

Day 2 – Friday 6 September 2024

08.00 — 09.00

Industry Symposia 2

Advances in Pathophysiology and Preventative Treatment of Migraine – Dr Farooq Maniyar and Dr Philip Holland PhD.

AbbVie Ltd.

Kensington Suite

09.00 — 10.30

Plenary 2

From basic through transitional to clinical practice and recommendations

Chair: Mario Peres (São Paulo Headache Center, Brazil)

Plenary Session 2
From basic through transitional to clinical practice and recommendations

Chair: Mario Peres

São Paulo Headache Center, Brazil

Kensington Suite
Personalised care and biomarkers (Depression and migraine)

Patricia Pozo-Rosich

Vall d’Hebron University Hospital, Spain

Review data on gender role in response to migraine treatment with acute and prophylactic drugs

Simona Sacco

University of L’Aquila, Italy

Practice Recommendations

Francesca Puledda

King’s College London, UK

Hypothalamus role in migraine

Rami Burstein

Harvard Medical School, US

Kensington Suite

10.30 — 11.00

Coffee Break

Richmond Suite

11.00 — 12.00

Oral Communications 1

Chair: Faisal Mohammad Amin
Copenhagen University Hospital, Denmark

LB.01 Efficacy Outcomes from a Phase 3, Randomised, Double- Blind, Placebo-Controlled Study of Fremanezumab for the Preventive Treatment of Episodic Migraine in Children and Adolescents Xiaoping Ning
O.01 The brainstem locus coeruleus and migraine. Veronica Munday
O.02 BoNT/A targets sensitized TRPV1-positive DRG neurons at therapeutic concentrations Mariana Nelson
O.03 Disrupted activation of pain networks during attack imagery in patients with episodic migraine Raquel Gil-Gouveia
O.04 Glucagon-like peptide-1 receptor agonists for the treatment of migraine: a pilot prospective observational study in a cohort of obese patients Simone Braca
O.05 Machine learning versus polygenic risk scoring as migraine predictors based on genome-wide genotype data Antonios Danelakis

Kensington Suite

12.00 — 13.00

Industry Symposia 3

This promotional symposium has been organised and funded by Lundbeck Ltd.

Lundbeck products will be discussed. The content of this presentation is for healthcare professionals

Kensington Suite

13.00 — 14.30

Lunch

Richmond Suite

13.05 — 13.35

 TAC Session (Mini-Oral Presentations)

Diana Wei
King’s College London

LB.02 Real-world evidence of clinical and demographic characteristics in cluster headache Helin Gosalia
MO.01 Efficacy and safety of eptinezumab in patients with
episodic cluster headache
(ALLEVIATE): A randomized
placebo-controlled trial
Anders Ettrup
MO.03 Role of specific microRNAs in cluster headache: correlation with disease phenotype and
neuropeptide levels
Francescantonio Cammarota
MO.04 Comparison between spontaneous and triggered
premonitory symptoms in CH
and migraine
Alicia Gonzalez-Martinez
MO.06 Analysis of MRI-based microstructural and functional
resting-state network
correlation: insights into the
activity of the hypothalamic-
thalamo-cortical network in
patients with episodic cluster
headache.
Gianluca Coppola

Kensington Suite

13.35 — 14.30

Digital Poster Booths Session 1

E-Poster Presentations
Session 1A
E-Poster Presentations
Session 1B
Chair: Roberta Messina,
IRCCS San Raffaele
Scientific Institute, Italy
Chair: Alicia González
Martínez,
Universidad Autónoma de
Madrid, Spain

Silent Theatres – Richmond Suite

14.30 — 15.30

Parallel Session 1

Migraine Aura: What is it?

Chair: Patricia Pozo-Rosich, Vall d`Hebron University Hospital & Institute of Research, Spain and Philip Holland (King’s College London, UK)

Parallel Session 1
Migraine Aura: what is it?

Chairs: Philip Holland
King’s College London, UK
& Patricia Pozo-Rosich Vall d`Hebron University Hospital & Institute of Research, Spain

Kensington
Suite
The bench view Else Tolner
Leiden University Medical Center,
Netherlands
 
The clinical view Michele Viana
King’s College London, UK
 

Kensington Suite

14.30 — 15.30

Parallel Session 2

Chair: Andreas Gantenbein (ZURZACH Care, Switzerland)

14:30 – 15:30

Parallel Session 2

Data

Chair: Andreas Gantenbein

ZURZACH Care, Switzerland

Admiral Suite

(Level -3, East Wing)

Assessing treatment efficacy: the role of randomized clinical trials

Edoardo Caronna

Vall d’Hebron University Hospital, Spain

 
Understanding treatment outcomes: the significance of real world data analysis

Nancy Van Veelan

Leiden University Medical Center, Netherlands

 
  Big data implications for understanding therapy

Erling Tronvik

NorHEAD, NTNU, Norway

 

Admiral Suite (Level -3)

15.30 — 16.00

Coffee Break

Richmond Suite

16.00 — 17.00

Plenary 3

Migraine Trust Lecture

Chair: Shazia Afridi (Guy’s and St Thomas’ Foundation Trust, UK)

Speaker: Rami Burstein (Harvard Medical School, USA)

Plenary 3 – Migraine Trust Lecture

Chair: Shazia Afridi

Guy’s and St Thomas’ Foundation Trust, UK

Rami Burstein

Harvard Medical School, US

Kensington Suite

Kensington Suite

17.00 — 18.00

Industry Symposia 4

Evidence based treatment of migraine with neuromodulation and how does the remote electrical neuromodulation (REN) work

Dr Reddy’s Laboratories (UK) Ltd.

Kensington Suite

Day 3 – Saturday 7 September 2024

07.30 — 08.30

Industry Symposia 5

Kensington Suite

08.30 — 10.00

Plenary 4

Sites of Action of Migraine Medications

Chair: Lars Edvinsson (University Hospital of Lund, Sweden) and Arne May (University of Hamburg, Germany)

Role of intracranial vasculature and infusion model Haider Al-Khazali
Danish Headache Center, Denmark
Key role of the nodes of Ranvier in the trigeminal system Jacob Edvinsson
Lund University, Sweden
Role of hypothalamus in migraine initiation Kuan-Po Peng
University Medical Center Hamburg- Eppendorf, Germany

Kensington Suite

10.00 — 10.30

Coffee Break

Richmond Suite

10.30 — 11.30

Parallel Session 3

Novel Targets and Treatment Challenges

Chair: Raquel Gil-Gouveia (Hospital da Luz, Portugal)

Vestibular migraine

David Moreno Ajona

King’s College London, UK

 
Greater occipital nerve injections

Debashish Chowdhury

GP Pant Institute of Post Graduate Medical Education and Research, New Delhi, India

 
Melatonin

Mario Peres

São Paulo Headache Center, Brazil

 
10:30 – 11:30

Parallel Session 4 Unravelling biomarkers for

migraine treatment: understanding treatment success (and failure)

Chair:

Todd Schwedt

Mayo Clinic, USA

 

Admiral Suite,

Level – 3, East Wing

Non-responders and super- responders to anti-CGRP treatment – what have we learned?

Piero Barbanti 

San Raffaele University, Italy

 
Delving into biomarkers of treatment response in chronic migraine

Irene de Boer

Leiden University Medical Center, Netherlands

 
Imaging biomarkers, can they help unlock insights into treatment success?

Roberta Messina

IRCCS San Raffaele Scientific Institute, Italy

 

Kensington Suite

10.30 — 11.30

Parallel Session 4

Unravelling biomarkers for migraine treatment: understanding treatment success (and failure)

Chair: Todd Schwedt (Mayo Clinic, USA)

  • Non-Responders and Super-Responders to Anti-CGRP Treatment: What have we learned?: Piero Barbanti
  • Delving Into Biomarkers of Treatment Response in Chronic Migraine: Irene de Boer
  • Imaging Biomarkers, Can They Help Unlock Insights Into Treatment Success?: Roberta Messina

Admiral Suite (Level -3)

11.30 — 12.30

Industry Symposia 6

From Trials to Treatment: Migraine Clinician Experiences 

Pfizer Ltd.

Kensington Suite

12.30 — 13.30

Lunch

30-Minute Product Theatre 2 

This promotional symposium has been organised and funded by Lundbeck Ltd.

Lundbeck products will be discussed. The content of this presentation is for healthcare professionals

Kensington Suite

13.30 — 14.30

Digital poster booths Session 

E-Poster Presentations
Session 2A
E-Poster Presentations
Session 2B
Chair: Edoardo Caronna,
Vall d’Hebron University
Hospital and Headache
Research Group, Spain
Chair: Roberto De Icco,
University of Pavia, Italy

Silent Theatres- Richmond Suite

14:30-15:00 Coffee Break Richmond Suite
13.30 — 14.30
Clinical Trial Themes (Mini-Oral Presentations)

Chair: Shazia Afridi,  Guys and St Thomas’ NHS Trust, United Kingdom

LB.03 Triptan non-response in a London tertiary headache centre: what can we learn? Robyn Wilcha
LB.04 The Safety and Effectiveness of Dual Calcitonin Gene-Related Peptide (CGRP) Therapies for Migraine Treatment: A Focus on Small Molecule Antagonist and Ligand Monoclonal Combinations Emily (Qu) Sonia Ukai
MO.07

Efficacy and safety of Lu AG09222 for migraine prevention in patients with 2–4 previous preventive treatment failures: HOPE, an interventional, randomized, double-blind, parallel-group,

placebo-controlled phase 2 trial

Elin Löf
MO.08 Practice variation in United Kingdom (UK) neurology management of episodic migraine Rafi Khan
MO.09 Effectiveness and predictors of response of intravenous dihydroergotamine in the treatment of primary headache disorders – A service evaluation Pubudu Amarasena
MO.10 Switching from ligand to receptor CGRP-mAb or vice versa in non responders: A Controlled Cohort Study Nancy Van Veelen
MO.11 OnabotulinumtoxinA (Botox) for Chronic Migraine during pregnancy; experience from Hull (UK) headache clinic over 12 years. Rafiullah Khan
MO.12 Real-world Switching Rates of Atogepant Are Lower Than CGRP Monoclonal Antibodies (mAbs) in Patients With Migraine Using Claims Database Pranav Gandhi

 

MO.13

Comparison of efficacy and safety of monoclonal antibodies targeting CGRP for Migraine prevention and age- related sub-groups analysis: a 12-months, multicenter, prospective, real-life study  Ilaria Cetta


Kensington Suite

14.30 — 15.00

Coffee Break

30-minute Product Theatre 3

Dr. Reddy’s Laboratories (UK) Ltd

Ricmond Suite

15.00 — 16.00

Oral Communications 2

Chair: Cristoph Schankin (University of Bern, Switzerland)

O.08 Predictors of migraine-related vertigo in adults and children Nazia Karsan
O.09 Evaluating a New Migraine Scoring System Against Established Metrics Patricia Pozo-Rosich
LB.05 αCGRP and βCGRP are co- expressed in the trigeminal ganglia Tayla Rees
LB.06 Stroke etiology and white matter hyperintensities in women with and without migraine Annelise Wilms
LB.07 The effect of selective adenosine A3 receptor (A3AR) agonists in preclinical models of migraine-like periorbital hypersensitivity Simon Akerman

Kensington Suite

16.00 — 17.00

Parallel Session 5

16.00-17.00

 

Parallel sessions

Parallel Session 5 Barriers to progress in headache care

Chairs: Rob Music The Migraine Trust, UK & Elena Ruiz de la Torre European Migraine and Headache Alliance (EMHA), Spain

Kensington Suite

 

Debashish Chowdhury

GB Pant Institute of Post Graduate Medical Education and Research, India

 

Rob Music

The Migraine Trust, UK

 

Elena Ruiz de la Torre

European Migraine and Headache Alliance (EMHA), Spain

 

Philip Holland

King’s College London, UK

 

 

16:00 – 17:00

Parallel Session 6

Elevated and low intracranial pressure and headache (and failure)

Chairs: Koen Paemeleire

Ghent University Hospital, Belgium

& Alex Sinclair

University of Birmingham, UK

Admiral Suite

Level -3, East Wing

 

Should I prescribe semaglutide for IIH?

Jonathan Hazelhurst

University of Birmingham, UK

 

Should I prescribe a CGRP blocking drug in IIH?

Andreas Yiangou

University of Birmingham, UK

Should I refer IIH patients for venous stenting?

Thomas Booth

King’s College Hospital NHS Foundation Trust UK

 

Kensington Suite

16.00 — 17.00

Parallel Session 6

Elevated and Low Intracranial Pressure and Headache

Chairs: Koen Paemeleire (Ghent University Hospital, Belgium) & Alex Sinclair (University of Birmingham, UK)

  • Should I prescribe semaglutide for IIH?: Jonathan Hazelhurst
  • Should I prescribe a CGRP blocking drug in IIH?: Andreas Yiangou
  • Should I refer IIH patients for venous stenting?: Thomas Booth

Admiral Suite (Level -3)

Day 4 – Sunday 8 September 2024

09.30 — 11.00

Plenary Session 5

Exploring the Relationship Between Migraine and Hormones

Chairs: Gisela Terwindt (Leiden University Medical Centre, Netherlands) & Raquel Gil Gouveia (Hospital da Luz, Portugal)

Plenary Session 5

Exploring the relationship between migraine and hormones

Chairs: Gisela Terwindt

Leiden University Medical Centre,Netherlands

& Raquel Gil-Gouveia , Hospital da Luz, Portugal

Oral contraceptives and migraine: what do you need to know?

Shazia Afridi

Guy’s and St Thomas’ Foundation Trust,UK

Perimenstrual migraine: treatment and prevention

Britt van der Arend

Leiden Headache Center, Netherlands

Migraine and pregnancy: insights, challenges and management strategies

Simona Sacco

University of L’Aquila, Italy

Kensington Suite

11.00 — 11.30

Coffee Break

Richmond Suite

11.30 — 12.00

Plenary Session 6

Plenary Session 6

 Cluster Award Lecture

Jacob C. A. Edvinsson, Lund University Sweden

Chair: Roberto De Icco

University of Pavia, Italy

Kensington Suite

Kensington Suite

12.00 — 12.30

Closing remarks

Kensington Suite